» Articles » PMID: 35683527

An Evaluation of the Physicochemical Properties of Preservative-Free 0.005% (/) Latanoprost Ophthalmic Solutions, and the Impact on In Vitro Human Conjunctival Goblet Cell Survival

Overview
Journal J Clin Med
Specialty General Medicine
Date 2022 Jun 10
PMID 35683527
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To examine the physicochemical properties of five preservative-free (PF) 0.005% latanoprost ophthalmic products; Monoprost, Latanest, Gaap Ofteno, Xalmono, and Xaloptic Free. Furthermore, the study investigated the mucin production and cell survival of primary cultured human conjunctival goblet cells when treated with PF eye drops.

Method: The pH value, osmolality, and surface tension were examined. Cell survival was analyzed using lactate dehydrogenase and tetrazolium dye colorimetric assays. Mucin production was analyzed with immunohistochemical staining.

Results: Monoprost (pH value 6.84 ± 0.032) had a pH value closest to the pH value of tear fluid (pH value 7.4-7.6), whereas Gaap Ofteno (pH value 6.34 ± 0.004) and Latanest (pH value 6.33 ± 0.003) had the lowest pH values. Gaap Ofteno (325.9 ± 2.9 mosmol/kg) showed iso-osmolar probabilities, whereas the other products were hypo-osmolar. Gaap Ofteno (60.31 ± 0.35 mN/m) had a higher surface tension compared to the tear fluid (40 to 46 mN/m), as described in the literature. No significant differences in goblet cell survival or mucin release were observed between the treatments and control.

Conclusion: Significant differences in pH value, osmolality, and surface tension were observed. However, this did not affect the viability of the goblet cells or the release of mucin. Clinical studies are required to evaluate the long-term effects of use on efficacy and safety.

Citing Articles

Enhancing the hypotensive effect of latanoprost by combining synthetic phosphatidylcholine liposomes with hyaluronic acid and osmoprotective agents.

Brugnera M, Vicario-de-la-Torre M, Gonzalez-Cela Casamayor M, Lopez-Cano J, Bravo-Osuna I, Huete-Toral F Drug Deliv Transl Res. 2024; 14(10):2804-2822.

PMID: 38602615 PMC: 11385046. DOI: 10.1007/s13346-024-01584-z.


Going for Gaps in Glaucoma.

Cvenkel B, Kolko M J Clin Med. 2023; 12(17).

PMID: 37685561 PMC: 10487839. DOI: 10.3390/jcm12175494.


Local production of eye drops in the hospital or pharmacy setting: considerations and safety tips.

Mohamed-Ahmed A, Kuguminkiriza D Community Eye Health. 2023; 36(118):17-18.

PMID: 37273803 PMC: 10236422.


Devices and Treatments to Address Low Adherence in Glaucoma Patients: A Narrative Review.

Cvenkel B, Kolko M J Clin Med. 2023; 12(1).

PMID: 36614952 PMC: 9821329. DOI: 10.3390/jcm12010151.

References
1.
Caprioli J, Varma R . Intraocular pressure: modulation as treatment for glaucoma. Am J Ophthalmol. 2011; 152(3):340-344.e2. DOI: 10.1016/j.ajo.2011.05.029. View

2.
Evangelista M, Koverech A, Messano M, Pescosolido N . Comparison of three lubricant eye drop solutions in dry eye patients. Optom Vis Sci. 2011; 88(12):1439-44. DOI: 10.1097/OPX.0b013e3182348c28. View

3.
Hsu K, Gupta K, Nayaka H, Donthi A, Kaul S, Chauhan A . Multidose Preservative Free Eyedrops by Selective Removal of Benzalkonium Chloride from Ocular Formulations. Pharm Res. 2017; 34(12):2862-2872. DOI: 10.1007/s11095-017-2270-8. View

4.
Honrubia F, Garcia-Sanchez J, Polo V, Martinez de la Casa J, Soto J . Conjunctival hyperaemia with the use of latanoprost versus other prostaglandin analogues in patients with ocular hypertension or glaucoma: a meta-analysis of randomised clinical trials. Br J Ophthalmol. 2008; 93(3):316-21. PMC: 2639645. DOI: 10.1136/bjo.2007.135111. View

5.
Van Santvliet L, Ludwig A . Determinants of eye drop size. Surv Ophthalmol. 2004; 49(2):197-213. DOI: 10.1016/j.survophthal.2003.12.009. View